Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

For medical-technology and pharmaceuticals manufacturing, “the most effective answer is not tariffs but tax policy,” Johnson ...

Reese Marketos played the role of government prosecutor in a False Claims Act case about alleged off-label use of an HIV drug ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.

If the FDA approves nipocalimab, the long-term data could form part of J&J’s pitch for the gMG market. The labels for ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

Q1 adjusted EPS of $2.77 beat estimates; cancer drug Darzalex sales jumped 20.3% ... % or 4.2 operationally to $13.90 billion. Also Read: Johnson & Johnson, Protagonist Tout Positive Results ...

Johnson & Johnson, while primarily known as America's leading healthcare company, now employs nearly 7,000 digital specialists and data scientists.

The chief executive of Johnson & Johnson has warned that potential ... Joe Wolk said the administration’s investigation into drug imports, widely seen as a first step toward imposing levies ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.